NICE, France & BUCHAREST, Romania--(BUSINESS WIRE)--Horus Pharma, an independent French company that is the leading player in ophthalmology, is announcing its first investment in a company outside France with the purchase of a significant participation in Inocare Pharm, a Romanian enterprise based in Bucharest, Romania. This strategic acquisition illustrates Horus Pharma’s goal of consolidating its international positions by acquiring established companies well known in their local market.
Founded ten years ago by a combined team of Romanian-Italian entrepreneurs, with solid experience in the pharmaceutical and especially ophthalmic business, Inocare Pharm was joined by Dr. Carmen Tudose as CEO in 2018. She has forged a strong reputation in the Romanian ophthalmological world through the successful launch of companies such as Biosooft Romania, a subsidiary of SOOFT Italy (currently Fidia) and Santen Japan.
Inocare Pharm specializes in the commercialization of medical devices, dietary supplements promoting eye health and diagnostic instruments, and it works with international manufacturers such as OFFHealth (Italy), Optima (Germany) and Tear Lab (United States). With its ten employees it generates revenue of €3 million (up 25% on the previous year).
Strategic alliance benefiting both partners
The acquisition of this shareholding represents an exceptional opportunity for Inocare Pharm. By joining forces with Horus Pharma, a leading European ophthalmology company, Inocare will expand its product portfolio and be able to introduce new drugs, to consolidate its position in the Romanian market and in the Balkans and ex CIS* territories.
For its part, Horus Pharma will gain access to rapidly growing Eastern European markets and help meet the needs of ophthalmologists and patients with its care offering and its effective and renowned solutions.
A fast growing market driven by the reimbursement of anti VEGF products and increase |
of AT segment and food supplements
|
|
Nicolas Claret, Horus Pharma’s International Director, commented: “This partnership represents a crucial growth driver that will help strengthen our international presence. By capitalizing on our pharmaceutical expertise, Inocare will be able to increase its market share in Romania, expand its influence in the Balkans and in central Asia. Our decision to join forces with a firmly established business such as Inocare Pharm will provide us with the backing of a committed and high-performance senior management team and give us access to experienced professionals able to effectively meet the needs of patients and health professionals. We are delighted to begin this new adventure alongside Carmen Tudose, and we have complete confidence in her ability to see this joint project through to fruition.”
Dr. Carmen Tudose, Chief Executive Officer and Founder of Inocare, added: “We are delighted that Horus Pharma is joining us as a shareholder. Over the past 20 years, it has established itself as a key player in Europe’s ophthalmology market by introducing innovative products, and we want to benefit from its considerable expertise. This strategic collaboration will expand our range and strengthen our position in our local market, as well as enabling us to move into the Balkans and other regions, where demand for high-quality ophthalmological solutions is growing rapidly.”
*Commonwealth of Independent States: CIS is an intergovernmental organization formed after the Soviet Union dissolved in 1991. The CIS includes countries that were previously Soviet republics and have chosen to preserve economic and political relations following the collapse of the USSR. |
About Horus Pharma www.horus-pharma.com
About Inocare Pharm www.inocare.ro
